Pentraxin 3 is Associated with Worse Outcome in Non-ST-Segment Elevation Myocardial Infarction

Tahir  Bezgin; Ali Elveran; Ali Karagoz; Ali Metin Esen

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Search Accepted Manuscripts

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Pentraxin 3 is Associated with Worse Outcome in Non-ST-Segment Elevation Myocardial Infarction

Author(s):

Tahir Bezgin^1,*,

Ali Elveran¹,

Ali Karagoz¹,

Ali Metin Esen¹

1Kartal Koşuyolu Heart and Research Hospital, Cardiology Clinic, Istanbul, Turkey

International Cardiovascular Research Journal:Vol. 9, issue 3; e11084

Published online:Sep 30, 2015

Article type:Research Article

Received:Feb 21, 2017

Accepted:Feb 28, 2015

How to Cite:Bezgin T, Elveran A, Karagoz A, Metin Esen A. Pentraxin 3 is Associated with Worse Outcome in Non-ST-Segment Elevation Myocardial Infarction.Int Cardiovasc Res J.2015;9(3):e11084.

Abstract

Background: Pentraxin 3 (PTX3) is a more specific marker of vascular inflammation than C - reactive protein (CRP).

Objectives: The present study aimed to demonstrate the association between PTX3 and markers of adverse events and poor prognosis in patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI).

Patients and Methods: This case-control study was conducted on 36 patients (10 females, mean age: 58 ± 11 years) with NSTEMI who had admitted to the Cardiology Clinic of Kartal Koşuyolu Heart Research Hospital and 35 age- and gender-matched healthy controls (26 females, mean age: 56 ± 9 years) between January and May 2013. PTX3 levels were measured in the controls and at the 8th and 24th hours of chest symptoms in the patients undergoing coronary angiography during admission.

Results: The patients group had significantly higher PTX-3 levels at both 8th and 24th hours compared to the control group (2.6 ± 3.1 vs. 1.9 ± 2.1 ng/mL, P < 0.001 at the 8th hour; 4.8 ± 7.6 vs. 1.9 ± 2.1 ng/mL, P < 0.010 at the 24th hour). The results showed a significant correlation between PTX3 level and Killip class (r = 0.34, P = 0.040 at the 8th hour; r = 0.43, P = 0.009 at the 24th hour). Besides, serum PTX3 level was positively correlated to the SYNTAX score (r = 0.57, P < 0.001 at the 8th hour) and negatively correlated to hemoglobin level (r = -0.37, P = 0.020).

Conclusions: Among the patients with NSTEMI, PTX3 level was associated with markers of higher risk and worse prognosis (GRACE score, hsCRP, age, NT-proBNP, and hemoglobin). Thus, PTX3 level might be used as a novel cardiac biomarker to determine high-risk patients.

Keywords

Acute Coronary Syndrome

Biological Markers

Myocardial Infarction

PTX3 Protein

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:1

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Tahir Bezgin:[PubMed][Scholar]
Ali Elveran:[PubMed][Scholar]
Ali Karagoz:[PubMed][Scholar]
Ali Metin Esen:[PubMed][Scholar]